Françoise Boyer‐Perrard

Efficacy and safety of pegylated‐interferon α‐2a in myelofibrosis: a study by the <scp>FIM</scp> and <scp>GEM</scp> French cooperative groups

Jean‐Christophe Ianotto, Françoise Boyer‐Perrard, Emmanuel Gyan et al. · British Journal of Haematology · 2013 · 78 citations · Full text

Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study

Jean‐Christophe Ianotto, Aurélie Chauveau, Françoise Boyer‐Perrard et al. · Haematologica · 2017 · 64 citations · Full text

EXPAND, a dose-finding study of ruxolitinib in patients with myelofibrosis and low platelet counts: 48-week follow-up analysis

Alessandro M. Vannucchi, Peter A.W. te Boekhorst, Claire Harrison et al. · Haematologica · 2018 · 46 citations · Full text

Ruxopeg, a Multi-Center Bayesian Phase 1/2 Adaptive Randomized Trial of the Combination of Ruxolitinib and Pegylated Interferon Alpha 2a in Patients with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis

Jean‐Jacques Kiladjian, Juliette Soret‐Dulphy, Matthieu Resche‐Rigon et al. · Blood · 2018 · 26 citations

Outcome of Ph negative myeloproliferative neoplasms transforming to accelerated or leukemic phase

Lise-Marie Mollard, Aurélie Chauveau, Françoise Boyer‐Perrard et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2018 · 20 citations

Hematological Malignancy, Transplantation, Elderly Patients +11